Study of Home Exercise and Sotatercept Treatment in Adults with Pulmonary Arterial Hypertension to Improve Function and Quality of Life

What this Trial Is About

Researchers are evaluating the use of sotatercept combined with a home exercise program for patients with pulmonary arterial hypertension PAH who are stable and ready to begin sotatercept therapy. This single-site study aims to assess the feasibility and functional outcomes associated with this combined intervention over a 24-week period. The study is led by the University of Washington and focuses on improving exercise capacity and quality of life in PAH patients. Participants will receive sotatercept as prescribed along with a tailored, progressive home exercise program monitored remotely using a wrist-worn fitness tracker and oxygen saturation device. The intervention period lasts 24 weeks, during which patients follow the exercise program with ongoing remote monitoring to support adherence and safety. Throughout the study, researchers will track recruitment and adherence rates, monitor study-related adverse events, and evaluate the fidelity of remote assessments such as the Six Minute Walk Test 6MWT. They will also measure changes in exercise capacity, cardiac effort, blood biomarkers, physical activity levels, and health-related quality of life. The total study duration for participants is 26 weeks, including all assessments and monitoring.

PAH Exercise Study